Luke Dow: The Complexity of Drug Resistance in Colorectal Cancer
Luke Dow, Professor at Weill Cornell Medicine, shared a post on LinkedIn:
“Second day in a row of KRAS inhibitor resistance papers! This time we worked backward from clinical data to reveal the complexity of drug resistance in colorectal cancer.
In collaboration with Rona Yaeger at Memorial Sloan Kettering Cancer Center, Salvador Alonso Martinez, Kevan Chu and others in our lab at Weill Cornell Medicine identified multiple, often co-existing modes of resistance to KRASi/EGFRi combination therapy. As part of this analysis, we identified a tumor cell-intrinsic inflammatory transcriptional response that when dampened, enhances the efficacy of KRAS inhibition.
We are continuing to explore this phenomenon and ways to short circuit triggers of therapy resistance.”
Title: Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC
Authors: Salvador Alonso, Kevan Chu, Marie J Parsons, Elizabeth Granowsky, Himari Gunasinghe, Jinru Shia, Rona Yaeger, Lukas E Dow
Read the Full Article.
More posts featuring Colorectal Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023